Key Takeaways
- Strong quarter, broad-based growth: Revenue grew ~40% YoY and EBITDA grew ~80% YoY, with both pharma and chemicals contributing. The non-ibuprofen portfolio is scaling fast, now 45% of pharma revenue.
- A capex cycle is now underway: Three projects totaling ~₹500 crores were announced: ibuprofen expansion, a formulation CDMO facility, and a specialty chemicals plant. The specialty plant is nearly commissioned and starts batches in November.
- Margins are structurally improving: EBITDA margin hit 14.4%, up 321 bps YoY, and management is targeting a sustainable blended margin of 15–17%. The CDMO business is expected to pull that higher once it ramps.
- Ibuprofen pricing is stable, not surging: Prices have been flat for several quarters and management expects them to stay at the same level for the next 2–3 quarters. The expansion is a volume play, not a price bet.
- What to watch next quarter: Whether the specialty chemical plant begins commercial batches on schedule in November, the trajectory of power and freight costs into Q3, and any early validation progress on the CDMO facility.
Performance Drivers
- Non-ibuprofen pharma is the growth engine: This portfolio grew ~70% YoY and now contributes 45% of pharma revenue, up from 38% a year ago. The diversification away from ibuprofen is reducing single-molecule concentration risk.
- Chemicals turned a corner: EBIT contribution improved to ~7% from ~1% in Q2 FY26, driven by better realizations, operating efficiencies, and disciplined procurement. Ethyl Acetate and Acetic Anhydride both ran at 100% capacity utilization.
- Ibuprofen is steady, not spiking: Prices have been stable for several quarters and remained flat in Q2. Capacity utilization has held at 90–95% for the last 3–4 quarters. The expansion to 18,000 MTPA is driven by customer engagement and internal CMO supply needs, not a peer-disruption thesis.
- Cost headwinds are seasonal, not structural: Other expenses rose to ~14.5% of sales due to higher summer power and fuel costs and elevated logistics freight. Management expects both to decrease in Q3 and Q4, and freight costs have capacity to be passed on to customers.
- Working capital stretched on growth: Finance costs rose YoY on higher working capital utilization to support increased volumes. Short-term borrowing peaked at ~₹200 crores as of 30 September 2026, with no additional borrowing expected given sufficient operating cash flow.
Mahajan: "We have sufficient cash flow operating and in hand cash with the company as of now."
Capital Projects: The Next Growth Cycle
- Three projects, ~₹500 crores total: The company announced an ibuprofen capacity expansion from 12,000 to 18,000 MTPA, a formulation CDMO facility with 150 crore tablets per year capacity, and a specialty chemicals facility under a long-term tolling arrangement with a global chemical company.
- Specialty chemicals plant is closest to revenue: The plant is almost commissioned and batches are expected to start in November, with gradual ramp-up per customer requirement. The arrangement is CMO-based on a cost-plus pricing model, giving visibility on realizations and profits. Product and customer details are confidential.
- CDMO facility is a margin story: European GMP certification and local state licensing approvals are already in place. The facility will initially convert existing API molecules like ibuprofen and paracetamol into bulk tablets and customized formats for the European market. Validation batches have already been given to anchor customers, with 1–2 quarters needed for complete validation. Commercialization is targeted for FY28.
- Ibuprofen expansion is a FY28–29 story: Equipment has already been ordered. Commissioning is targeted for FY28, with optimum utilization expected in FY28–29. The incremental capacity is expected to serve both new API customers and internal CMO supply, with a rough 50-50 split.
- CDMO margins expected to lift the blend: Management stated CDMO commands better margins than API products, though it is too early to discuss specific numbers. The sustainable blended EBITDA target of 15–17% factors in this uplift over time.
Singh: "The benefit is there that we have visibility of the realizations and the profits as well. Also, this opens us the opportunities for entering the CDMO business for the chemicals also."
Ibuprofen: Pricing, Capacity & Strategy
- Prices are flat and expected to stay that way: Ibuprofen prices have been stable for several quarters and remained unchanged in Q2. Management expects them to remain at the same level for the next 2–3 quarters, and calls forecasting 2–3 years out "risky" given current dynamism.
- The expansion is customer-led, not speculative: Management framed the capacity increase as a strategic initiative aligned with current high utilization and ongoing customer engagement, explicitly stating it is not related to peer developments.
- Utilization is already tight: Ibuprofen capacity utilization has been 90–95% for the last 3–4 quarters, leaving little headroom for incremental volume without the expansion.
- Paracetamol pricing held despite input cost pressure: Acetic acid prices rose 50% in September, but paracetamol prices remained almost flat versus the previous quarter. Acetic acid is not a direct input for paracetamol but feeds into acetic anhydride, which is then used in manufacturing.
Singh: "I think considering there's so much dynamism in the current situation, forecasting 2, 3 years, prices of the Ibuprofen from there is risky for me."
Regulatory & Market Access Milestones
- Three approvals strengthen the export story: The company received a Certificate of Suitability from EDQM for Fenofibrate-Process II, taking total CEP approvals to 22. It also secured EU-REACH registrations for triacetin and GMP certification for the formulation CDMO facility.
- Triacetin plant is ready, awaiting commercial orders: The plant has started and REACH registration is in hand, but commercial orders have not yet been finalized. Customer discussions are ongoing and some customers are visiting the facility.
- CDMO customer approval timeline is ~1 year: From the start of validation, management expects approximately one year, plus or minus 3–4 months, for customer approval in the respective country.
Order Book & Demand Visibility
- Four to six quarters of order book: Visibility is primarily for Ibuprofen, Paracetamol, and Metformin, providing a reasonable runway for the base business while new projects ramp.
- Export growth is coming from diversification: Incremental export growth was driven by increased penetration in chemicals, specifically Ethyl Acetate, and mainly contributed by the non-Ibu segment.
- Chemicals growth was price and volume both: The 38% growth in chemicals came from 100% capacity utilization for Ethyl Acetate and Acetic Anhydride, plus better prices. Management declined to break out volume versus price when asked.
Margins & Cost Structure
- EBITDA margin expanded 321 bps YoY to 14.4%: The improvement was driven by product mix, operational efficiencies, better capacity utilization, and disciplined execution. PAT more than doubled YoY in H1 to ~₹130 crores.
- Management targets 15–17% sustainable blended EBITDA: This is framed as a realistic target rather than an aspirational one.
- Seasonal cost pressures should ease: Power and fuel costs rose due to summer seasonality, and logistics freight was elevated. Both are expected to decrease in Q3 and Q4.
- Finance costs reflect growth, not distress: The YoY increase in finance costs is tied to higher working capital utilization to support increased business operations and volumes. Working capital limits are in place and not fully utilized.
Singh: "I think the sustainable — I think we should rather than being aspirational, we should talk more on the sustainable EBITDA number. So around 15% to 17% is a sustainable number, and we should target that."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 revenue growth | 25% plus revenue growth, surpassing previous ~₹2,700 Cr guidance | FY27 full year |
| FY27 EBITDA margin | 14–15% EBITDA margin | FY27 full year |
| H2 FY27 performance | Q3 and Q4 expected to have more or less same performance as H1 | Q3 and Q4 FY27 |
| Ibuprofen expansion commissioning | 12,000 to 18,000 MTPA; optimum utilization in FY28–29 | FY28 |
| CDMO facility commercialization | 150 crore tablets/year; validation batches already with anchor customers | FY28 |
| Specialty chemicals plant start | Batches expected to start in November; gradual ramp-up | November (Q3 FY27) |
| Ibuprofen pricing | Expected to remain at same level | Next 2–3 quarters |
| Sustainable blended EBITDA | 15–17% target | Medium-term (no date) |
| Capex for FY27 | ₹250 crores planned; ~half spent in H1, remainder in H2 | FY27 |
| Peak short-term borrowing | ~₹200 crores; no additional borrowing expected | As of 30 Sep 2026 |
| Other expenses (power, freight) | Expected to decrease | Q3 and Q4 FY27 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹795 cr, ~40% YoY and high single-digit QoQ |
| H1 FY27 revenue | ₹1,551 cr, ~39% YoY |
| EBITDA | ~₹115 cr, ~80% YoY (vs ₹64 cr in Q2 FY26) |
| EBITDA margin | 14.4%, improved 321 bps YoY (vs 11.2% in Q2 FY26) |
| H1 FY27 EBITDA | ~₹227 cr, ~70% YoY; margin 14.5% (vs 11.8% in H1 FY26) |
| Profit after tax | ~₹65 cr, ~117% YoY (vs ₹30 cr in Q2 FY26) |
| H1 FY27 PAT | ~₹130 cr, more than doubled YoY (vs ₹64 cr in H1 FY26) |
| Non-ibuprofen pharma revenue growth | ~70% YoY, contributing 45% of pharma revenue (vs 38% in Q2 FY26) |
| Chemicals business EBIT contribution | ~7% of overall EBIT (vs ~1% in Q2 FY26) |
| Exports contribution | ~28% of H1 FY27 revenue |
| Ibuprofen capacity utilization | ~90% to 95% for last 3–4 quarters |
| FY27 revenue growth guidance | 25% plus |
| FY27 EBITDA margin guidance | 14% to 15% |
| Chemicals segment growth | 38% in Q2 |
| Planned capex for FY27 | ₹250 cr, ~half spent in H1, remainder in H2 |
| Short-term borrowing | ₹200 cr as of 30 Sep 2026, stated as peak working capital for the rest of the year |